Advertisement

Characterization of plasma daptomycin in patients with serum highly glycated albumin and obesity

Published:October 14, 2022DOI:https://doi.org/10.1016/j.jiac.2022.10.002

      Abstract

      Purpose

      Plasma daptomycin has not been fully characterized in diabetic and obese patients. This study aimed to evaluate the associations of plasma daptomycin with glycation of serum albumin and obesity.

      Methods

      Infectious patients (n = 70) receiving intravenous daptomycin were enrolled. The plasma concentration of total and free daptomycin were determined using liquid chromatograph-tandem mass spectrometer. The associations of the plasma concentrations of daptomycin with clinical factors including serum albumin fractionations and physical status (obese including overweight, body mass index ≥ 25.0) were investigated. Daptomycin doses were adjusted using total body-weight.

      Results

      The serum albumin level was positively and negatively correlated with the plasma concentration of total daptomycin and its free fraction proportion, respectively. The serum non-glycated albumin was negatively correlated with the free fraction proportion. The dose-normalized plasma concentration of total daptomycin was higher in the obese patients than in non-obese patients when the body-weight was corrected with total and adjusted values. For the dose adjustment with lean body-weight, no difference was observed in the dose-normalized plasma concentration of total daptomycin between the physical statuses. For each body-weight correction method, physical status did not affect the dose-normalized plasma concentration of free daptomycin.

      Conclusion

      The glycation of serum albumin and obesity did not associate with dose-normalized plasma free daptomycin. In obese patients, daptomycin dosage adjustment with total body-weight and adjusted body-weight may lead to an apparent excessive exposure resulting in overdosage compared to lean body-weight.

      Keywords

      Abbreviations:

      DAP (daptomycin), MRSA (methicillin-resistant Staphylococcus aureus), tDAP (total daptomycin), fu (unbound fraction proportion), fDAP (free daptomycin), CK (creatine phosphokinase), FBS (fasting blood glucose), TBW (total body-weight), ABW (adjusted body-weight), LBW (lean body-weight), eGFR (estimated glomerular filtration rate), IQR (interquartile range), BMI (body mass index), WHO (World Health Organization), IBW (ideal body weight)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Infection and Chemotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gregoire N.
        • Chauzy A.
        • Buyck J.
        • Rammaert B.
        • Couet W.
        • Marchand S.
        Clinical pharmacokinetics of daptomycin.
        Clin Pharmacokinet. 2021; 60: 271-281https://doi.org/10.1007/s40262-020-00968-x
        • Osorio C.
        • Garzón L.
        • Jaimes D.
        • Silva E.
        • Bustos R.H.
        Impact on antibiotic resistance, therapeutic success, and control of side effects in therapeutic drug monitoring (TDM) of daptomycin: a scoping review.
        Antibiotics (Basel). 2021; 10: 263https://doi.org/10.3390/antibiotics10030263
        • Kim A.
        • Suecof L.A.
        • Sutherland C.A.
        • Gao L.
        • Kuti J.L.
        • Nicolau D.P.
        In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers.
        Antimicrob Agents Chemother. 2008; 52: 3941-3946https://doi.org/10.1128/AAC.00589-08
        • Grillon A.
        • Argemi X.
        • Gaudias J.
        • Ronde-Ousteau C.
        • Boeri C.
        • Jenny J.Y.
        • et al.
        Bone penetration of daptomycin in diabetic patients with bacterial foot infections.
        Int J Infect Dis. 2019; 85: 127-131https://doi.org/10.1016/j.ijid.2019.05.011
        • Bhavnani S.M.
        • Rubino C.M.
        • Ambrose P.G.
        • Drusano G.L.
        Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis.
        Clin Infect Dis. 2010; 50: 1568-1574https://doi.org/10.1086/652767
        • Woodworth J.R.
        • Nyhart Jr., E.H.
        • Brier G.L.
        • Wolny J.D.
        • Black H.R.
        Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers.
        Antimicrob Agents Chemother. 1992; 36: 318-325https://doi.org/10.1128/aac.36.2.318
        • Grégoire N.
        • Marchand S.
        • Ferrandière M.
        • Lasocki S.
        • Seguin P.
        • Vourc'h M.
        • et al.
        Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment.
        J Antimictob Chemother. 2019; 74: 117-125https://doi.org/10.1093/jac/dky374
        • Dvorchik B.
        • Robert D.A.
        • Chung J.
        • Liu S.
        • Knebel W.
        • Kastrissios H.
        Population pharmacokinetics of daptomycin.
        Antimicrob Agents Chemother. 2004; 48: 2799-2807https://doi.org/10.1128/AAC.48.8.2799-2807.2004
        • Enokiya T.
        • Muraki Y.
        • Iwamoto T.
        • Okuda M.
        Changes in the pharmacokinetics of teicoplanin in patients with hyperglycaemic hypoalbuminaemia: impact of albumin glycosylation on the binding of teicoplanin to albumin.
        Int J Antimicrob Agents. 2015; 46: 164-168https://doi.org/10.1016/j.ijantimicag.2015.03.010
        • Sugioka N.
        • Sato K.
        • Haraya K.
        • Maeda Y.
        • Yasuda K.
        • Fukushima K.
        • et al.
        Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavirin rats.
        Biopharm Drug Dispos. 2008; 29: 469-479https://doi.org/10.1002/bdd.633
        • Zendjabil M.
        Glycated albumin.
        Clin Chim Acta. 2020; 502: 240-244https://doi.org/10.1016/j.cca.2019.11.007
        • Samura M.
        • Takada K.
        • Yamamoto R.
        • Ito H.
        • Nagumo F.
        • Uchida M.
        • et al.
        Population pharmacokinetic analysis and dosing optimization based on unbound daptomycin concentration and cystatin C in nonobese elderly patients with hypoalbuminemia and chronic kidney disease.
        Pharm Res. 2021; 38: 1041-1055https://doi.org/10.1007/s11095-021-03058-0
        • Dare R.K.
        • Tewell C.
        • Harris B.
        • Wright P.W.
        • Van Driest S.L.
        • Farber-Eger E.
        • et al.
        Effect of statin coadministration on the risk of daptomycin-associated myopathy.
        Clin Infect Dis. 2018; 67: 1356-1363https://doi.org/10.1093/cid/ciy287
        • Lehman B.
        • Neuner E.A.
        • Heh V.
        • Isada C.
        A retrospective multisite case-control series of concomitant use of daptomycin and statins and the effect on creatine phosphokinase.
        Open Forum Infect Dis. 2019; 6: ofz444https://doi.org/10.1093/ofid/ofz444
        • Bookstaver P.B.
        • Bland C.M.
        • Qureshi Z.P.
        • Faulkner-Fennell C.M.
        • Sheldon M.A.
        • Caulder C.R.
        • et al.
        Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States.
        Pharmacotherapy. 2013; 33: 1322-1330https://doi.org/10.1002/phar.1298
        • Polso A.K.
        • Lassiter J.L.
        • Nagel J.L.
        Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review.
        J Clin Pharm Therapeut. 2014; 39: 584-608https://doi.org/10.1111/jcpt.12200
        • Pai M.P.
        • Norenberg J.P.
        • Anderson T.
        • Goade D.W.
        • Rodvold K.A.
        • Telepak R.A.
        • et al.
        Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
        Antimicrob Agents Chemother. 2007; 51: 2741-2747https://doi.org/10.1128/AAC.00059-07
        • Fox A.N.
        • Smith W.J.
        • Kupiec K.E.
        • Harding S.J.
        • Resman-Targoff B.H.
        • Neely S.B.
        • et al.
        Daptomycin dosing in obese patients: analysis of the use of adjusted body weight versus actual body weight.
        Ther Adv Infect Dis. 2019; 6: 1-10https://doi.org/10.1177/2049936118820230
        • Butterfield-Cowper J.M.
        • Lodise Jr., T.P.
        • Pai M.P.
        A fixed versus weight-based dosing strategy of daptomycin may improve safety in obese adults.
        Pharmacotherapy. 2018; 38: 981-985https://doi.org/10.1002/phar.2157
        • Miyadera Y.
        • Naito T.
        • Yamada T.
        • Kawakami J.
        Simple LC-MS/MS methods using core–shell octadecylsilyl microparticulate for the quantitation of total and free daptomycin in human plasma.
        Ther Drug Monit. 2018; 40: 589-595https://doi.org/10.1097/FTD.0000000000000535
        • Galar A.
        • Muñoz P.
        • Valerio M.
        • Cercenado E.
        • García-González X.
        • Burillo A.
        • et al.
        Current use of daptomycin and systematic therapeutic drug monitoring: clinical experience in a tertiary care institution.
        Int J Antimicrob Agents. 2019; 53: 40-48https://doi.org/10.1016/j.ijantimicag.2018.09.015
        • Matsuo S.
        • Imai E.
        • Horio M.
        • Yasuda Y.
        • Tomita K.
        • Nitta K.
        • et al.
        Revised equations for estimated GFR from serum creatinine in Japan.
        Am J Kidney Dis. 2009; 53: 982-992https://doi.org/10.1053/j.ajkd.2008.12.034
        • Finfer S.
        • Bellomo R.
        • McEvoy S.
        • Lo S.
        • Myburgh J.
        • Neal B.
        • et al.
        • SAFE study investigators
        Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study.
        BMJ. 2006; 333: 1044https://doi.org/10.1136/bmj.38985.398704.7C
        • World Health Organization
        Obesity and overweight.
        • Lemmens H.J.
        • Brodsky J.B.
        • Bernstein D.P.
        Estimating ideal body weight - a new formula.
        Obes Surg. 2005; 15: 1082-1083https://doi.org/10.1381/0960892054621350
        • Meng L.
        • Mui E.
        • Holubar M.K.
        • Deresinski S.C.
        Comprehensive guidance for antibiotic dosing in obese adults.
        Pharmacotherapy. 2017; 11: 1415-1431https://doi.org/10.1002/phar.2023
        • Wurtz R.
        • Itokazu G.
        • Rodvold K.
        Antimicrobial dosing in obese patients.
        Clin Infect Dis. 1997; 25: 112-118https://doi.org/10.1086/514505
        • Ando M.
        • Nishioka H.
        • Nakasako S.
        • Kuramoto E.
        • Ikemura M.
        • Kamei H.
        • et al.
        Observational retrospective single-centre study in Japan to assess the clinical significance of serum daptomycin levels in creatinine phosphokinase elevation.
        J Clin Pharm Therapeut. 2020; 45: 290-297https://doi.org/10.1111/jcpt.13061
        • Dvorchik B.H.
        • Brazier D.
        • DeBruin M.F.
        • Arbeit R.D.
        Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.
        Antimicrob Agents Chemother. 2003; 47: 1318-1323https://doi.org/10.1128/AAC.47.4.1318-1323.2003
        • Mohr 3rd, J.F.
        • Ostrosky-Zeichner L.
        • Wainright D.J.
        • Parks D.H.
        • Hollenbeck T.C.
        • Ericsson C.D.
        Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury.
        Antimicrob Agents Chemother. 2008; 52: 1891-1893https://doi.org/10.1128/AAC.01321-07
        • Zeitlinger M.A.
        • Derendorf H.
        • Mouton J.W.
        • Cars O.
        • Craig W.A.
        • Andes D.
        • et al.
        Protein binding: do we ever learn?.
        Antimicrob Agents Chemother. 2011; 55: 3067-3074https://doi.org/10.1128/AAC.01433-10
        • Benet L.Z.
        • Hoener B.A.
        Changes in plasma protein binding have little clinical relevance.
        Clin Pharmacol Ther. 2002; 71: 115-121https://doi.org/10.1067/mcp.2002.121829
        • Toutain P.L.
        • Bousquet-Melou A.
        Free drug fraction vs free drug concentration: a matter of frequent confusion.
        J Vet Pharmacol Therapeut. 2002; 25: 460-463https://doi.org/10.1046/j.1365-2885.2002.00442.x
        • Sudlow G.
        • Birkett D.J.
        • Wade D.N.
        Further characterization of specific drug binding sites on human serum albumin.
        Mol Pharmacol. 1976; 12: 1052-1061
        • Barras M.
        • Legg A.
        Drug dosing in obese adults.
        Aust Prescr. 2017; 40: 189-193https://doi.org/10.18773/austprescr.2017.053
        • Reiber C.
        • Senn O.
        • Müller D.
        • Kullak-Ublick G.A.
        • Corti N.
        Therapeutic drug monitoring of daptomycin: a retrospective monocentric analysis.
        Ther Drug Monit. 2015; 37: 634-640https://doi.org/10.1097/FTD.0000000000000196